Cargando…
Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease...
Autores principales: | Levine, Anne E., Mark, Dominique, Smith, Laila, Zheng, Hengqi B., Suskind, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059893/ https://www.ncbi.nlm.nih.gov/pubmed/36986830 http://dx.doi.org/10.3390/pharmaceutics15030969 |
Ejemplares similares
-
The Growing Need to Understand Very Early Onset Inflammatory Bowel Disease
por: Zheng, Hengqi B., et al.
Publicado: (2021) -
Higher Morbidity of Monogenic Inflammatory Bowel Disease Compared to the Adolescent Onset Inflammatory Bowel Disease
por: Kim, Kwang Yeon, et al.
Publicado: (2018) -
Recent Advance in Very Early Onset Inflammatory Bowel Disease
por: Shim, Jung Ok
Publicado: (2019) -
Recent advance in very early-onset inflammatory bowel disease
por: Shim, Jung Ok
Publicado: (2019) -
Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019)